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Abstract
Background:  Few  studies  compare  the  therapeutic  efﬁcacy  of  different  iron  deﬁciency  anaemia
treatments.
Aim: Evaluate  the  therapeutic  response  of  the  most  common  iron  preparations.
Material  and  methods: Retrospective,  observational-analytical  study  based  on  medical  records
from the  Haematology  Department,  conducted  from  March  to  October  2014,  including  121  adults
with ferropenic  anaemia  and  3-month  follow-up.  Patients  with  comorbidities  or  pregnancy  were
excluded.
Results: 85.8%  were  women  (n  =  103)  and  14%  men  (n  =  17),  with  a  mean  age  of  42  (16--83)  years.
Seventy patients  (58.3%)  started  with  oral  administration;  the  rest  received  intravenous  iron.
Efﬁcacy was  similar  among  all  the  iron  preparations,  with  no  signiﬁcant  differences  (p  >  0.05).
Iron sucrose  was  most  effective  in  rapidly  replenishing  body  iron  stores.
Conclusions:  Despite  comparable  efﬁcacy  among  treatments,  ferrous  fumarate  had  the  lowest
treatment  failure  and  was  the  therapy  of  choice.
© 2015  Published  by  Masson  Doyma  México  S.A.  on  behalf  of  Sociedad  Médica  del  Hospital
General  de  México.PALABRAS  CLAVE
Anemia  ferropénica;
Adulto;
Compuestos  férricos;
Análisis  retrospectivo  de  la  respuesta  terapéutica  obtenida  con  hierro  enteral  y
parenteral  en  adultos  con  anemia  por  deﬁciencia  de  hierro
Resumen
Antecedentes:  Escasos  estudios  comparan  la  eﬁcacia  terapéutica  entre  tratamientos  para
anemia ferropénica.∗ Corresponding author at: Dr. Balmis 148, Col. Doctores, C.P. 06726 Mexico City, Mexico.
E-mail address: leukemiachop@hotmail.com (C.O. Ramos-Pen˜aﬁel).
ttp://dx.doi.org/10.1016/j.hgmx.2015.08.005
185-1063/© 2015 Published by Masson Doyma México S.A. on behalf of Sociedad Médica del Hospital General de México.
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Resultado  del
tratamiento;
Administración  oral
Objetivo:  Evaluar  el  efecto  terapéutico  de  las  formulaciones  de  hierro  más  empleadas.
Materiales  y  método:  Estudio  retrospectivo,  observacional-analítico  basado  en  los  expedientes
del Servicio  de  Hematología  desde  marzo  a  octubre  de  2014,  incluyendo  121  adultos  con  anemia
ferropénica  con  seguimiento  de  3  meses,  excluyendo  casos  con  comorbilidades  y  embarazadas.
Resultados:  El  85.8%  fueron  mujeres  (n  =  103)  y  14.2%  hombres  (n=17),  con  edad  media  de  42
(16-83) an˜os.  Setenta  pacientes  (58.3%)  iniciaron  tratamiento  vía  oral,  el  resto  vía  endovenoso.
La eﬁcacia  fue  mejor  para  fumarato  ferroso  (p=0.001)  y  hierro  sacarosa  (p=0.000).  Hierro
sacarosa  restituye  rápida  y  óptimamente  las  reservas  corporales  de  hierro.
Conclusiones:  A  pesar  de  la  efectividad  equiparable  entre  tratamientos,  fumarato  ferroso  fue
el predilecto  con  menor  falla  terapéutica.
© 2015  Publicado  por  Masson  Doyma  México  S.A.  en  nombre  de  Sociedad  Médica  del  Hospital
General de  México.
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SIntroduction
Nearly  half  of  all  reported  cases  of  anaemia  worldwide
are  secondary  to  iron  deﬁciency.  Despite  the  existence  of
guidelines  for  the  management  of  anaemia,  controversy  still
surrounds  the  diagnosis  and  treatment  of  this  disease,  and
this  uncertainty  contributes  to  an  average  of  841,000  deaths
each  year,  and  35,057,000  disability-adjusted  life  years.1
In  contrast  to  other  pathologies,  iron  deﬁciency  anaemia
can  present  at  all  stages  of  life,  either  as  a  primary  or
comorbid  disease  (for  example,  in  chronic  kidney  failure
or  restless  legs  syndrome).2 Situations  such  as  pregnancy,
menstruation,  or  body  growth  are  most  commonly  asso-
ciated  with  the  development  of  iron  deﬁciency  anaemia.
Recently,  however,  other  pathologies  such  as  heart  fail-
ure  or  inﬂammatory  bowel  syndrome  have  also  been  linked
to  a  high  prevalence  of  iron  deﬁciency.  Standard  treat-
ment  is  oral  administration  of  iron,  usually  in  the  form
of  ferrous  sulphate  (325  mg  [65  mg  of  elemental  iron]  3
times  daily).3 Oral  iron  can  cause  side  effects,  such  as
reﬂux,  constipation,  diarrhoea,  nausea  or  ﬂatulence,  and
is  not  effective  in  some  patients.  In  these  cases,  par-
enteral  administration  of  iron  should  be  considered.4 The
beneﬁts  of  intravenous  iron  supplementation  have  mainly
been  evaluated  in  patients  with  chronic  kidney  failure.  The
most  commonly  used  formulations  are  iron  dextran,  fer-
ric  gluconate,  iron  sucrose,  ferumoxytol,  iron  isomaltose,
or  carboxymaltose.5 In  Mexico,  iron  dextran  is  the  intra-
venous  therapy  of  choice,  although  dextran-derived  ligands
or  compounds  can  cause  anaphylactic  shock.6 In  a  recent
study,  Alvarado-Ibarra  et  al.7 reported  a  0.26%  prevalence  of
adverse  events  associated  with  iron  dextran  infusion.  Mex-
ico  has  a  high  prevalence  of  iron  deﬁciency,  particularly
among  the  more  underprivileged  population  groups  (20%
vs.14%).8 Nevertheless,  few  studies  have  evaluated  the  ther-
apeutic  efﬁcacy  of  the  different  formulations  available  or
the  management  of  patients  with  iron  deﬁciency  anaemia
not  secondary  to  pregnancy  or  chronic  kidney  failure.  Diag-
nosis  and  follow-up  should  not  be  limited  exclusively  to
normalizing  haemoglobin  levels,9,10 as  these  alone  have  low
sensitivity  and  speciﬁcity  for  diagnosing  and  monitoring  iron
deﬁciency  anaemia.  Instead,  other  haematological  parame-
ters  such  as  mean  corpuscular  volume  (MCV)  and  Wintrobe
S
(
tndices,  together  with  other  recently  discovered  biomarkers
uch  as  zinc  protoporphyrin  and  reticulocyte  haemoglobin
hould  be  used.  All  these  are  highly  effective  screening
ools,  and  help  quantify  anaemia  severity  and  guide  the
nitial  management  strategy.11--13 Greater  insight  into  iron
etabolism  has  shown  that  haemoglobin  and  mean  cor-
uscular  volume  are  the  last  parameters  to  be  affected  in
ron  deﬁciency  anaemia;  serum  ferritin  and  iron  levels  are
ltered  ﬁrst,  and  are  therefore  invaluable  markers  in  the
iagnosis  of  iron  deﬁciency  anaemia  and  the  estimation  of
ody  iron  reserves.14--16
The  primary  aims  of  this  study  were  to  evaluate  the  efﬁ-
acy  of  different  iron  therapy  regimens  in  increasing  both
aemoglobin  levels  and  red  blood  cell  count,  and  their  rela-
ionship  with  iron  kinetics.
ethods
tudy  design
 retrospective,  analytical  observational  study  based  on
he  clinical  records  of  patients  treated  in  the  Haematol-
gy  Department  between  March  and  October  2014.  Patients
hat  met  diagnostic  criteria  for  iron  deﬁciency  anaemia
Table  1)  were  included.  Only  patients  with  previous  diag-
osis  of  chronic  kidney  failure,  cancer,  or  pregnancy  were
xcluded.  Convenience  sampling  methods  were  used,  so  all
ases  that  met  the  study  criteria  were  included.  Cases  with
ncomplete  follow-up,  deﬁned  as  loss  to  follow-up  up  to  3
onths  after  start  of  treatment,  were  excluded.  Treatment
esponse  was  deﬁned  as  a  2  g/dL  increase  in  haemoglobin
evels  over  a  period  of  3--4  weeks;  treatment  failure  was
eﬁned  as  an  increase  of  less  than  1  g/dL  over  a period
f  4  weeks.  The  formulation  used  and  the  route  of  admin-
stration  were  chosen  at  the  discretion  of  the  attending
hysician.
tatistical  analysistudy  data  were  analysed  using  IBM  SPSS  version  20.0
Armonk,  New  York)  for  Windows.  The  mean  and  mode  of
he  haemoglobin  levels  and  red  blood  cell  count  resulting
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Table  1  Diagnostic  criteria  for  iron  deﬁciency  anaemia.
Criterion  Men  Women
Haemoglobin  <14  g/dLa <13  g/dLa
Reference  range:  16.1  ±  0.8  (+1)  g/dL  14.3  ±  0.68  (+1)  g/dL
Hematocrit <39%a <36%a
Reference  range:  47.6  ±  2.5  (+3)%  42.4  ±  2.13  (+3)%
Serum ferritin  <20  ng/mL  <20  ng/mL
Reference range:  40--300  ng/mL  20--200  ng/mL
Serum iron  <60  ng/mL  <60  ng/mL
Reference range: 60--170  ng/mL 60--170  ng/mL
a lev
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ta Values adjusted for the altitude of Mexico City (2250 m above se
rom  different  treatment  regimens  were  analysed  descrip-
ively.  The  mean  difference  in  haemoglobin  levels  among
ntravenous  and  oral  therapies  was  calculated  using  the
tudent’s  t  test.  The  mean  difference  between  different
t
c
c
Table  2  Main  patient  characteristics  and  results  of  whole  blood  
Characteristics  n  
Gender
Women  103  
Men 17  
Cause
Iron deﬁciency  (no  other  pathology) 5  
Rheumatoid  arthritis/lupus  5  
Liver failure  4  
Major depression/schizophrenia  2  
Type 2  diabetes  mellitus  1  
Hyperthyroidism  1  
Hypothyroidism  7  
Chronic kidney  failure  1  
Pemphigus  1  
Upper gastrointestinal  bleeding  25  
Angiodysplasia  1  
Dysfunctional  uterine  bleeding  62  
Benign tumour  (uterine  myositis)  1  
Cancer 4  
Blood count  at  diagnosis  Mean  
Haemoglobin  (g/dL)  8.4  
Haematocrit  (%)  27.9  
Mean corpuscular  volume  (fL)  65.4  
Mean corpuscular  haemoglobin  (pg)  19.9  
Blood cell  distribution  width  (%)  19.9  
Reticulocytes  (%)  1.05  
Leukocytes  (×103/mcL)  6.48  
Neutrophils  (×103/mcL)  3.98  
Lymphocytes  (×103/mcL)  1.84  
Platelets (×103/mcL)  357.8  
Ferritin (ng/mL)  8.0  
Serum iron  (mcg/dL)  19.4  
Iron saturation  (%)  5.5  
Iron binding  capacity  (mcg/dL)  436.46
Transferrin (mg/dL)  377.7  
Iron deﬁcit  (mcg/dL)  957.8  el. Factor used shown in brackets).
herapies  used  was  calculated  using  the  single  factor  ANOVA
est.  The  therapeutic  failure  hypothesis  was  tested  using  the
hi-square  test,  with  a  signiﬁcance  of  p  ≤  0.05  and  a  95%
onﬁdence  interval.
count  at  diagnosis.
(%)
85.8
14.2
4.1
4.1
3.3
1.6
0.8
0.8
5.8
0.8
0.8
20.8
0.8
51.6
0.8
3.3
Median  Range
8.6  5.2--12.5
28.3  17.2--38.2
64.5  52.2--80.4
19.6  14.2--30.2
20  13.2--36.4
0.5  0--8.2
6.25  2.3--15.1
3.7  1.3--13
1.7  1.68--5.7
351.5  50--824
4.5  1.0--56
18  7.0--65
4.3  1.0--16.5
 438  186--597
396.5  4.68--527
1121  245--2284
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Table  3  Exogenous  iron  supplements  administered.
Iron  formulation  Supplement
Ferrous  fumarate
350  mg
Iron  polymaltose
357,143  mg
Iron  sucrose
2.700  mg
Pharmaceutical  form  Tablet  Tablet  5  mL  ampoule
Route of  administration  Oral  Oral  Intravenous
Elemental  iron
equivalent
115  mg  100  mg  100  mg
Dose regimen 1  tablet  every  24  h  for  3
months
1  tablet  every  12  h  for  3
months
Total  dose  =  patient
weight  (kg)  ×  (target
haemoglobin  −  current
haemoglobin)  ×  2.4
× 500  [estimated
reserves]
Divide  the  total  dose  to
deliver  3  ×  200  mg
weekly  (600  mg/week)
for  1  month  or
200  mg/week  for  2
months,  depending  on
the  calculated  deﬁcit
Adverse effects  Nausea,  upper  abdomen
pain,  constipation
Nausea,  upper  abdomen
pain
Fever
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wEthical  considerations
The  trial  was  submitted  to  and  approved  by  the  Independent
Ethics  Committee  of  the  General  Hospital  of  Mexico.  Due  to
its  retrospective  nature,  no  signed  informed  consent  forms
were  required,  and  patient  privacy  and  data  anonymity  were
preserved  at  all  times,  in  accordance  with  prevailing  laws.
Results
In  total,  120  patients  met  inclusion  criteria  and  their  records
were  analysed  for  the  purpose  of  this  study;  85.8%  were
women  (n  =  103)  and  14.2%  were  men  (n  =  17).  The  overall
mean  age  was  42  years  (range  16--83  years);  the  mean  age
of  men  was  slightly  higher  than  that  of  women  (52  vs.  41
years).  Over  50%  of  patients  presented  symptoms  associ-
ated  with  anaemia,  although  less  speciﬁc  symptoms,  such  as
pica,  were  found  in  44.2%  of  cases  (n  =  53).  The  most  com-
mon  ﬁndings  on  physical  examination  were  pallor  and  hair
loss;  koilonychia  was  found  in  45.5%  of  cases  (n  =  55).  The
aetiology,  complete  blood  count,  and  iron  kinetics  at  the
time  of  diagnosis  are  shown  in  Table  2.  The  most  common
aetiology  was  abnormal  uterine  bleeding  (51.2%),  in  most
cases  associated  with  uterine  myomatosis.  This  was  followed
by  upper  gastrointestinal  bleeding  (20.6%),  in  most  cases
due  to  gastric  ulcers  or  erosive  gastritis.  The  least  common
causes  included  psychiatric  disorders,  in  1.6%,  and  hypothy-
roidism  in  around  5.8%  of  patients.  Iron  deﬁciency  preceded
diagnosis  in  0.08%  of  cases  of  diabetes  mellitus,  chronic
kidney  failure,  and  even  pregnancy.  Iron  deﬁciency  was
signiﬁcantly  associated  with  diagnosis  of  digestive  cancer
(colon  cancer)  in  2.5%  of  cases.  Most  of  these  patients  were
a
f
f
1en  (n  =  3).  Oral  and  intravenous  therapy  dose  regimens  are
hown  in  Table  3.  The  main  adverse  effects  associated  with
ral  administration  were:  nausea,  upper  abdomen  pain  and
onstipation;  intravenous  iron  administration  caused  fever
n  4  patients.
reatment
pproximately  58.3%  of  patients  (n  =  70)  were  started  on
ral  therapy,  and  41.6%  (n  =  50)  on  intravenous  admin-
stration.  The  preparations  most  commonly  used  were
errous  fumarate  and  iron  polymaltose.  The  only  intra-
enous  formulation  used  was  iron  sucrose  (iron  deﬁcit  was
alculated  on  the  basis  of  the  following  formula:  total
ose  =  patient  weight  (kg)  ×  (target  haemoglobin  −  current
aemoglobin)  ×  2.4  ×  500  [estimated  reserves]).  In  19.9%  of
ases  therapy  was  changed  (n  =  24)  due  to  treatment  failure;
ron  polymaltose  therapy  failed  in  19.2%,  and  therapy  was
ither  changed  to  intravenous  iron  sucrose  or  to  oral  ferrous
umarate,  the  latter  with  a  failure  rate  of  0.7%  (Table  4).
reatment  efﬁcacy
he  follow-up  period  was  3  months.  Patients  were  eval-
ated  at  2  weeks  after  start  of  treatment,  then  at  1
onth,  and  ﬁnally  at  3  months.  As  a  result  of  the  thera-
ies  used,  haemoglobin  levels  increased  by  1--2  g/dL  at  2
eeks  after  start  of  treatment;  the  best  responses  were
chieved  with  ferrous  fumarate  and  iron  sucrose.  No  dif-
erences  in  haemoglobin  levels  were  found  between  ferrous
umarate  and  iron  sucrose  (p  =  0.575  at  2  weeks,  p  =  0.490  at
 month,  p  =  0.490  at  3  months).  Ferrous  fumarate  showed
116  
Table  4  Percentage  use  of  different  therapies.
Treatment  n  %
Ferrous  fumarate  monotherapy  32  26.7
Iron polymaltose  14  11.7
Iron sucrose  23  19.2
Iron sucrose  +  oral  maintenance  therapy  27  22.5
Therapeutic  failure
Ferrous  fumarate  to  iron  sucrose  1  0.7
Iron polymaltose  to  iron  sucrose  9  7.5
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ine  bleeding  secondary  to  uterine  myomatosis.  This  wasIron polymaltose  to  ferrous  fumarate 14  11.7
etter  response  compared  with  iron  polymaltose  at  3  months
p  = 0.175  at  2  weeks,  p  =  0.426  at  1  month  and  p  =  0.001  at  3
onths).  Increase  in  ferritin  levels  was  greater  with  ferrous
umarate  and  iron  sucrose  overall;  in  comparison,  ferrous
umarate  performed  better  than  iron  polymaltose  (p  =  0.004
nd  1  month  and  p  =  0.001  at  3  months).  Response  with  intra-
enous  iron  (iron  sucrose)  was  superior  to  oral  iron  (p  =  0.000
t  both  1  and  3  months)  (Table  5).  Fig.  1A  shows  haemoglobin
f
p
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Table  5  Comparison  of  haemoglobin  and  ferritin  levels  with  diffe
Haemoglobin
Baseline  2  weeks  
Ferrous  fumarate  8.57  (5.3--11.7)  10.08  (6--11.9
Iron polymaltose  9.98  (7.9--10.5)  10.74  (6.8--13
Iron sucrose  7.83  (5.3--10)  9.83  (6.8--13.
T test  re
Ferrous fumarate
vs. iron
polymaltose
0.003* 0.175  
Ferrous  fumarate
vs. iron  sucrose
0.079  0.575  
Ferrous fumarate
or iron
polymaltose  vs.
iron  sucrose
0.002* 0.130  
Ferritin  (ng
Baseline  2  weeks  
Ferrous  fumarate  6.20  (1.2--26.9)  NA  
Iron polymaltose  8.89  (2.4--26)  NA  
Iron sucrose  11.71  (1.2--56)  NA  
T test  re
Ferrous fumarate
vs. iron
polymaltose
0.161  NA  
Ferrous  fumarate
vs. iron  sucrose
0.031  NA  
Ferrous  fumarate
or iron
polymaltose  vs.
iron  sucrose
0.367  NA  
* Statistically signiﬁcant.G.  Barragán-Iban˜ez  et  al.
evels  and  mean  corpuscular  volume.  Fig.  1B  shows  serum
erritin  and  iron  levels.
iscussion
ron  deﬁciency  anaemia  is  a  public  health  problem  in
oth  developed  and  developing  countries.  It  affects  peo-
le  at  all  stages  of  life,  but  is  most  prevalent  in  women
f  childbearing  age,  pregnant  women,  and  children  under
 years  of  age.  The  most  common  cause  of  iron  deﬁ-
iency  anaemia  in  adolescent  and  adult  women  is  vaginal
aemorrhage  due  to  dysfunctional  uterine  bleeding  or  sec-
ndary  to  uterine  myomatosis.  In  adults  of  both  sexes,  iron
eﬁciency  anaemia  is  caused  by  chronic  pathologies:  gas-
rointestinal  haemorrhage  (erosive  gastritis,  gastric  ulcers,
olyps,  intestinal  diverticula  or  colon  cancer).17,18 In  our
tudy,  we  found  a  predominance  of  female  patients.  The
ost  common  cause  of  anaemia  was  dysfunctional  uter-ollowed  by  upper  gastrointestinal  bleeding  (Helicobacter
ylori  gastritis),  autoimmune  diseases  such  as  hypothy-
oidism,  and  colon  cancer,  predominantly  in  men,  consistent
rent  therapies  over  3-month  follow-up.
 (g/dL)
Month  3  months
)  11.74  (8.3--13.9)  13.56  (11.6--15.5)
.2)  11.39  (9.3--13)  12.46  (10.6--14.6)
2)  12.05  (8--15.1)  13.97  (13.1--14.6)
sult
0.426  0.001*
0.490  0.305
0.686  0.416
/mL)
Month  3  months
20.51  (7.8--44.2)  28.68  (10.5--56)
12.20  (4--28.2)  17.90  (9.3--36)
162.08  (34.6--512)  213.86  (63--724.8)
sult
0.004* 0.001*
0.000* 0.000*
0.000* 0.000*
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dFigure  1  Complete  blood  count  (A)  and  iron  kinetics  (B)
with  literature.19,20 Patients  present  the  typical  symptoms  of
anaemia,  such  as  weakness,  headaches,  irritability,  tinnitus,
phosphenes  and  koilonychia,  although  many  patients  were
asymptomatic.  The  clinical  manifestations  were  largely  sim-
ilar  in  all  study  patients,  the  only  notable  ﬁnding  being
koilonychia  in  45.5%  (n  =  55).  Diagnosis  of  iron  deﬁciency
anaemia  was  made  on  the  basis  of  haemoglobin  levels,
Wintrobe  indexes,  and  more  importantly,  mean  corpuscular
volume,  the  latter  being  the  most  important  marker  in  red
blood  cell  indices.  Other  ﬁndings  used  to  conﬁrm  iron  deﬁ-
ciency  anaemia  are  higher  red  blood  cell  distribution  width
W
s
t
smeters  with  different  therapies  over  3-month  follow-up.
nd  low  ferritin  levels,  all  of  which  were  present  in  study
atients.  Some  patients  presented  platelet  counts  of  up  to
00,000,  an  unusual  ﬁnding  in  patients  with  iron  deﬁciency
naemia.
The  aim  of  therapy  is  to  normalize  haemoglobin  lev-
ls  and  Wintrobe  indices,  and  replenish  iron  reserves.  Iron
eﬁciency  therapy  should  start  with  dietary  strategies.21,22hen  anaemia  is  severe,  exogenous  oral  or  intravenous  iron
upplements  should  be  started.  Several  different  formula-
ions  based  on  different  iron  salts  are  available  (ferrous
ulphate,  ferrous  fumarate,  iron  polymaltose,  iron  dextran,
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218  
ron  sucrose,  and  ferric  carboxymaltose).14,23,24 The  recom-
ended  dose  for  oral  therapy  in  adults  is  100  to  200  mg  of
lemental  iron  daily24,27.  In  the  Haematology  Department
f  the  Hospital  General  of  Mexico,  we  give  our  patients
errous  fumarate,  iron  polymaltose  and  iron  sucrose.  Iron
extran  has  not  been  used  for  6  years,  due  to  a  higher  risk
f  anaphylactic  shock.  In  this  study,  we  compared  treatment
esponse  over  3  months  in  order  to  evaluate  the  efﬁcacy
f  each  of  these  3  preparations.  Ferrous  fumarate  and  iron
ucrose  were  equally  effective  and  better  than  iron  polymal-
ose  in  normalizing  haemoglobin  and  serum  iron  levels  and
ean  corpuscular  volumes,  while  ferritin  level  increase  was
reater  with  iron  sucrose  vs.  all  oral  formulations.  Compar-
ng  ferritin  increase  in  oral  formulations  (ferrous  fumarate
nd  iron  polymaltose),  better  results  were  obtained  with
errous  fumarate.
In conclusion,  oral  and  intravenous  administration  of  iron
alts  are  similarly  effective  in  anaemia  therapy  (normaliza-
ion  of  haemoglobin  levels  and  MCV);  iron  sucrose  is  more
ffective  in  restoring  iron  reserves.  However,  we  believe
hat  oral  iron  supplements  should  be  continued  for  3  months
n  order  to  restore  total  iron  reserves,  and  the  best  oral  sup-
lement  is  ferrous  fumarate.  Controlled  clinical  trials  are
eeded  to  conﬁrm  this  observation.
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